AdipoGen Life Sciences

anti-LAG-3 (human), mAb (17B4) (ATTO 488)

CHF 490.00
In stock
AG-20B-0012TD-T100100 testsCHF 490.00
More Information
Product Details
Synonyms Lymphocyte Activation Gene-3; FDC Protein; CD223
Product Type Monoclonal Antibody
Properties
Clone 17B4
Isotype Mouse IgG1κ
Source/Host Purified from concentrated hybridoma tissue culture supernatant.
Immunogen/Antigen Synthetic peptide corresponding to 30 aa in the N-terminus of human LAG-3.
Label/Conjugates ATTO 488
Application

Flow Cytometry: (1:100)
Immunocytochemistry

Definition for 1 test: 1μl of labeled antibody in 200μl of Flow Cytometry buffer (see online protocol).

Crossreactivity Human
Specificity

Recognizes human LAG-3.

Purity ≥95% (SDS-PAGE)
Purity Detail Protein G-affinity purified.
Concentration 1mg/ml
Formulation Liquid. In PBS containing 0.02% sodium azide.
Isotype Negative Control

Mouse IgG1 Isotype Control (ATTO 488)

Other Product Data

New ATTO-fluorescent antibodies show increased photostability, outstanding brightness and intense signals. ATTO dyes are thermally stable, resistant to environmental changes and show no significant isomerization.
ATTO 488 shows bright green fluorescence (λabs (max): 501nm, λem (max): 523nm, εmax: 90’000).

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Do not freeze.
Protect from light.
Use/Stability Keep conjugated formats at +4°C.
Stable for at least 1 year after receipt when stored at +4°C.
Documents
Protocols Download PDF
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

Lymphocyte activation gene 3 (LAG-3; CD223) plays an important role in negatively regulating T cell proliferation, function and homeostasis. It is required for maximal natural and induced regulatory T cell (Treg) function. LAG-3 is closely related to the T cell co-receptor CD4 and binds to MHC class II molecules but with a significantly higher affinity than CD4.

Product References
  1. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens: E. Baixeras, et al.; J. Exp. Med.176, 327 (1992) 
  2. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand: B. Huard, et al.; Immunogenetics 39, 213 (1994)
  3. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein: B. Huard, et al.; PNAS 94, 5744 (1997) 
  4. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling: S. Hannier, et al.; J. Immunol. 161, 4058 (1998) 
  5. T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts: C.E. Demeure, et al.; Eur. J. Cancer 37, 1709 (2001) 
  6. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway: E.D. Carlo, et al.; J. Pathol. 205, 82 (2005) 
  7. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells: L. Macon-Lemaitre and F. Triebel; Immunology 115,170 (2005) 
  8. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors: F. Triebel, et al.; Cancer Lett. 235, 147 (2006) 
  9. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells: J. Bayry, et al.; J. Immunol. 178, 4184 (2007) 
  10. Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation: C. Casati, et al.; J. Immunol. 180, 3782 (2008)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.